125 related articles for article (PubMed ID: 3002265)
1. Differential metabolism of (E)-5-(2-bromovinyl)-2'-deoxyuridine in wild-type and drug-resistant herpes simplex virus-infected cells.
Ayisi N; Wall R; De Clercq E; Sacks S
Antiviral Res; 1985; Suppl 1():45-9. PubMed ID: 3002265
[No Abstract] [Full Text] [Related]
2. Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.
Balzarini J; De Clercq E
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):379-89. PubMed ID: 2545982
[No Abstract] [Full Text] [Related]
3. Selective inhibition of the proliferation of herpes simplex virus type 1 thymidine kinase gene-transformed murine mammary FM3A carcinoma cells by (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
Balzarini J; De Clercq E; Ayusawa D; Shimizu K; Seno T
Nucleic Acids Symp Ser; 1985; (16):283-6. PubMed ID: 3003708
[TBL] [Abstract][Full Text] [Related]
4. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
Balzarini J; de Clercq E; Ayusawa D; Seno T
FEBS Lett; 1985 Jun; 185(1):95-100. PubMed ID: 2987041
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
[TBL] [Abstract][Full Text] [Related]
6. Selection of L cell sublines resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Shiraki K; Vonka V; De Clercq E; Rapp F
Intervirology; 1991; 32(4):228-33. PubMed ID: 1650764
[TBL] [Abstract][Full Text] [Related]
7. (E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity.
Bernaerts R; Desgranges C; De Clercq E
Biochem Pharmacol; 1989 Jun; 38(12):1955-61. PubMed ID: 2545207
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the interaction of monophosphates of the antiviral nucleosides 2'-fluoro-1-beta-D-arabinofuranosylpyrimidine and (E)-5-(2-bromovinyl)-2'-deoxyuridine with thymidylate kinases from Vero cells and herpes simplex virus types 1 and 2.
Chen MS; Amico LA; Speelman DJ
Antimicrob Agents Chemother; 1984 Nov; 26(5):778-80. PubMed ID: 6083755
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
10. 5-Methoxymethyldeoxyuridine-resistant mutants of herpes simplex virus type 1.
Veerisetty V; Gentry GA
Virology; 1981 Oct; 114(2):576-9. PubMed ID: 6270889
[No Abstract] [Full Text] [Related]
11. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.
Bubley G; Crumpacker C; De Clercq E; Schnipper L
Virology; 1983 Sep; 129(2):490-2. PubMed ID: 6312685
[TBL] [Abstract][Full Text] [Related]
12. Alterations in substrate specificity and physicochemical properties of deoxythymidine kinase of a drug-resistant herpes simplex virus type 1 mutant.
Veerisetty V; Gentry GA
J Virol; 1983 Jun; 46(3):901-8. PubMed ID: 6304349
[TBL] [Abstract][Full Text] [Related]
13. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.
Crumpacker CS; Schnipper LE; Marlowe SI; Kowalsky PN; Hershey BJ; Levin MJ
N Engl J Med; 1982 Feb; 306(6):343-6. PubMed ID: 6275267
[No Abstract] [Full Text] [Related]
14. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.
Coen DM; Irmiere AF; Jacobson JG; Kerns KM
Virology; 1989 Feb; 168(2):221-31. PubMed ID: 2536980
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
16. Differential binding affinities of sugar-modified derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine for herpes simplex virus-induced and human cellular deoxythymidine kinases.
Zou FC; Dutschman GE; De Clercq E; Cheng YC
Biochem Pharmacol; 1984 Jun; 33(11):1797-800. PubMed ID: 6329218
[TBL] [Abstract][Full Text] [Related]
17. Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.
Field HJ; Neden J
Antiviral Res; 1982 Oct; 2(5):243-54. PubMed ID: 6295272
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the recognition of nucleoside analogues as substrates by the deoxythymidine kinase of a 5-methoxymethyldeoxyuridine-resistant mutant of herpes simplex virus type 1.
Veerisetty V; Veerisetty IK; Gentry GA
J Gen Virol; 1983 Dec; 64 ( Pt 12)():2767-70. PubMed ID: 6319559
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex acyclovir-resistant mutant in experimental keratouveitis.
Boisjoly HM; Park NH; Pavan-Langston D; De Clercq E
Arch Ophthalmol; 1983 Nov; 101(11):1782-6. PubMed ID: 6314952
[TBL] [Abstract][Full Text] [Related]
20. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus.
Fyfe JA
Mol Pharmacol; 1982 Mar; 21(2):432-7. PubMed ID: 6285172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
